3-(4-iodophenoxy)propionic acid | 67856-44-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-iodophenoxy)propionic acid
• 英文别名: 3-(4-Iodophenoxy)propanoic acid
• CAS: 67856-44-4
• 化学式: C₉H₉IO₃
• 分子量: 292.073
• InChiKey: RZGJRFGFQBJVDR-UHFFFAOYSA-N

物化性质

• 熔点：
  160-161 °C
• 沸点：
  350.2±22.0 °C(Predicted)
• 密度：
  1.790±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-iodophenoxy)propionic acid 在 phosphorus pentoxide 、 苯 作用下， 生成 3-dimethylaminomethyl-6-iodo-chroman-4-one
  参考文献：
  名称：

  Sen; Arora, Journal of the Indian Chemical Society, 1958, vol. 35, p. 95,97

  摘要：

  DOI：
• 作为产物：
  描述：

  4-碘苯酚 生成 3-(4-iodophenoxy)propionic acid
  参考文献：
  名称：

  Biphenyl hydroxamate inhibitors of matrix metalloproteinases

  摘要：

  式##STR1##的化合物或其药用可接受的盐抑制基质金属蛋白酶和TNF.alpha.分泌，并且在治疗炎症性疾病状态中是有用的。还公开了抑制基质金属蛋白酶和TNF.alpha.分泌的组合物和抑制基质金属蛋白酶和TNF.alpha.分泌的方法。

  公开号：

  US05665777A1

文献信息

• ＢＥＴ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途
  申请人：田辺三菱製薬株式会社

  公开号：WO2020009176A1

  公开（公告）日：2020-01-09

  がん細胞に対する細胞傷害作用、がん細胞におけるＢＥＴ蛋白質の分解を誘導する作用、およびＢＥＴ蛋白質とアセチル化ヒストンとの結合阻害作用に優れ、抗がん剤、ＢＥＴ蛋白質の分解誘導剤及びＢＥＴ蛋白質阻害剤として有用な化合物を提供すること。下記一般式（Ｉ）で表される化合物又はその薬理学的に許容される塩。｛式中、各記号は明細書中で定義した通りである。｝

  对癌细胞具有细胞损伤作用，诱导癌细胞中BET蛋白质的降解作用，以及优越的BET蛋白质与乙酰化组蛋白结合抑制作用，提供作为抗癌药物、BET蛋白质降解诱导剂和BET蛋白质抑制剂有用的化合物。该化合物或其药理学上可接受的盐由下述通用式（I）表示。式中，各符号如在说明书中定义。}
• AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3819305A1

  公开（公告）日：2021-05-12

  Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor. A compound represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof

  本发明提供了一种化合物，该化合物对癌细胞具有卓越的细胞毒性作用、诱导癌细胞中 BET 蛋白降解的作用以及抑制 BET 蛋白与乙酰化组蛋白结合的作用，可用作抗癌剂、BET 蛋白降解诱导剂或 BET 蛋白抑制剂。下式（I）代表的化合物 其中各符号如说明书中所定义，或其药理上可接受的盐
• Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR
  作者：P. J. Hajduk、G. Sheppard、D. G. Nettesheim、E. T. Olejniczak、S. B. Shuker、R. P. Meadows、D. H. Steinman、G. M. Carrera、P. A. Marcotte、J. Severin、K. Walter、H. Smith、E. Gubbins、R. Simmer、T. F. Holzman、D. W. Morgan、S. K. Davidsen、J. B. Summers、S. W. Fesik

  DOI：10.1021/ja9702778

  日期：1997.6.1

  With the use of an NMR-based method, potent (IC50 < 25 nM) nonpeptide inhibitors of the matrix metalloproteinase stromelysin (MMP-3) were discovered. The method, called SAR by NMR (for structure-activity relationships by nuclear magnetic resonance), involves the identification, optimization, and linking of compounds that bind to proximal sites on a protein. Using this technique, two ligands that bind weakly to stromelysin (acetohydroxamic acid, K-D = 17 mM; 3-(cyanomethyl)-4'-hydroxybiphenyl, K-D = 0.02 mM) were identified. On the basis of NMR-derived structural information, the two fragments were connected to produce a 15 nM inhibitor of this enzyme. This compound was rapidly discovered (less than 6 months) and required only a minimal amount of chemical synthesis. These studies indicate that the SAR by NMR method can be effectively applied to enzymes to yield potent lead inhibitors-an important part of the drug discovery process.
• Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA
  作者：Shrinivas D. Joshi、Uttam A. More、Deepshikha Koli、Manoj S. Kulkarni、Mallikarjuna N. Nadagouda、Tejraj M. Aminabhavi

  DOI：10.1016/j.bioorg.2015.03.001

  日期：2015.4

  Enoyl acyl carrier protein reductase (ENR) is an essential type II fatty acid synthase (FAS-II) pathway enzyme that is an attractive target for designing novel antitubercular agents. Herein, we report sixty-eight novel pyrrolyl substituted aryloxy-1,3,4-thiadiazoles synthesized by three-step optimization processes. Three-dimensional quantitative structure-activity relationships (3D-QSAR) were established for pyrrolyl substituted aryloxy-1,3,4-thiadiazole series of InhA inhibitors using the comparative molecular field analysis (CoMFA). Docking analysis of the crystal structure of ENR performed by using Surflex-Dock in Sybyl-X 2.0 software indicates the occupation of pyrrolyl substituted aryloxy 1,3,4-thiadiazole into hydrophobic pocket of InhA enzyme. Based on docking and database alignment rules, two computational models were established to compare their statistical results. The analysis of 3D contour plots allowed us to investigate the effect of different substituent groups at different positions of the common scaffold. In vitro testing of ligands using biological assays substantiated the efficacy of ligands that were screened through in silico methods. (C) 2015 Elsevier Inc. All rights reserved.
• An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1
  作者：Erin M. Wilfong、Yu Du、Eric J. Toone

  DOI：10.1016/j.bmcl.2012.05.032

  日期：2012.10

  Fragment based drug discovery remains a successful tool for pharmaceutical lead discovery. Although based upon the principle of thermodynamic additivity, the underlying thermodynamic basis is poorly understood. A thermodynamic additivity analysis was performed using stromelysin-1 and a series of biphenyl hydroxamate ligands identified through fragment additivity. Our studies suggest that, in this instance, additivity arises from enthalpic effects, while interaction entropies are unfavorable; this thermodynamic behavior is masked by proton transfer. Evaluation of the changes in constant pressure heat capacities during binding suggest that solvent exclusion from the binding site does not account for the dramatic affinity enhancements observed. (c) 2012 Elsevier Ltd. All rights reserved.